Eczacibasi Ilac Sanayi ve T.A.S. operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eczacibasi Ilac Sanayi ve T.A.S. with three other
pharmaceutical manufacturers in Europe:
Horizon Discovery Group PLC
of the United Kingdom
sales of £58.73 million [US$72.42 million]
of which 79%
(113.04 million Euro [US$124.49 million]
of which 92%
was Commercialized Vaccines), and
Moberg Pharma AB (publ)
based in Sweden
(439.04 million Swedish Kronor [US$45.38 million]
of which 40%
was Kerasal Nail /Nalox).
Eczacibasi Ilac Sanayi ve T.A.S. reported sales of 692.09 million Turkish Liras (US$120.33 million)
December of 2018.
increase of 15.8%
versus 2017, when the company's sales were 597.91 million Turkish Liras.
Despite this increase, sales are still
below the level achieved in 2016, when Eczacibasi Ilac Sanayi ve T.A.S.
reported sales of 1.41 billion Turkish Liras.